Placenta-tropic VEGF mRNA lipid nanoparticles ameliorate murine pre-eclampsia.

ABSTRACT: Pre-eclampsia is a placental disorder that affects 3-5% of all pregnancies and is a leading cause of maternal and fetal morbidity worldwide^1,2. With no drug available to slow disease progression, engineering ionizable lipid nanoparticles (LNPs) for extrahepatic messenger RNA (mRNA) delivery to the placenta is an attractive therapeutic option for pre-eclampsia. Here we use high-throughput screening to evaluate a library of 98 LNP formulations in vivo and identify a placenta-tropic LNP (LNP 55) that mediates more than 100-fold greater mRNA delivery to the placenta in pregnant mice than a formulation based on the Food and Drug Administration-approved Onpattro LNP (DLin-MC3-DMA)³. We propose an endogenous targeting mechanism based on β₂-glycoprotein I adsorptio

SUBMITTER: Swingle KL 

PROVIDER: S-EPMC12205896 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature